Stereotaxis (NYSEAMERICAN:STXS) Now Covered by Analysts at Citizens Jmp

Analysts at Citizens Jmp initiated coverage on shares of Stereotaxis (NYSEAMERICAN:STXS) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set a “market outperform” rating and a $4.00 price target on the stock. Citizens Jmp’s price target suggests a potential upside of 72.41% from the company’s current price.

STXS has been the topic of several other reports. UBS Group set a $4.00 price objective on shares of Stereotaxis in a report on Wednesday, November 5th. Roth Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. Finally, Citigroup assumed coverage on shares of Stereotaxis in a report on Tuesday. They issued an “outperform” rating on the stock. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Stereotaxis currently has an average rating of “Buy” and an average target price of $4.00.

Stereotaxis Trading Down 2.1%

Stereotaxis stock opened at $2.32 on Tuesday. The stock has a fifty day moving average price of $2.68 and a 200 day moving average price of $2.58. Stereotaxis has a 52 week low of $1.54 and a 52 week high of $3.59. The firm has a market capitalization of $216.50 million, a P/E ratio of -8.29 and a beta of 1.47.

Insider Buying and Selling at Stereotaxis

In other Stereotaxis news, Director Paul J. Isaac purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was purchased at an average cost of $2.24 per share, with a total value of $44,800.00. Following the transaction, the director owned 2,786,557 shares in the company, valued at approximately $6,241,887.68. This trade represents a 0.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 17.77% of the company’s stock.

Institutional Investors Weigh In On Stereotaxis

Large investors have recently modified their holdings of the stock. Warberg Asset Management LLC raised its holdings in shares of Stereotaxis by 260.1% during the 2nd quarter. Warberg Asset Management LLC now owns 1,201,500 shares of the company’s stock valued at $2,547,000 after buying an additional 867,878 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Stereotaxis during the third quarter valued at approximately $1,125,000. Prescott Group Capital Management L.L.C. lifted its position in shares of Stereotaxis by 44.5% during the second quarter. Prescott Group Capital Management L.L.C. now owns 1,139,252 shares of the company’s stock worth $2,415,000 after purchasing an additional 350,600 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Stereotaxis by 4.2% in the third quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after purchasing an additional 138,482 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new stake in Stereotaxis during the 3rd quarter worth $413,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.